A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
暂无分享,去创建一个
J. Sosman | T. Kuzel | S. Fisher | Joseph I. Clark | T. Lestingi | J. Clark | M. Viola | P. Sorokin | B. Martone